The Sugar Beat

 
 

  • Top 5 Medications That Can Increase Blood Glucose Levels Many medications potentially disrupt glycemic control. Akshay Jain, MD, provides an overview of the top 5 and tips to avoid disruption.
  • Mercury Rising: Ambient Temperature and Blood Sugar This summer's hot temperatures can cause deleterious effects on people with diabetes. Akshay Jain, MD, explains why it's important to educate people with diabetes about the potential risks.
  • Medications Within Borders: Canada Limits Ozempic Purchase A growing influx of US residents purchasing Ozempic in Canada led to a move to limit sales to Canadian residents. Dr Jain questions whether it's time to reevaluate prescription costs in the US.
  • Fitting-Room Approach for Diabetes Meds: Try It First Letting patients choose their own medications is not the norm, but a recent study of patients with diabetes found that when offered a choice, patients actually chose the best medication for them.
  • Meditation Instead of Medication in Type 2 Diabetes? Recent studies suggest that mind-body practices can improve glycemic control in patients with type 2 diabetes. Dr Akshay Jain provides insight into this research.
  • Putting the Patient First: Top Insights From ADA 2022   From new guidelines for managing glucose to possible remission of type 2 diabetes, Dr Akshay Jain reviews what he feels are the most important studies from the ADA Scientific Sessions.
  • The Burden of Undiagnosed Diabetes Dr Jain reviews the International Diabetes Federation Atlas, predicting an 'alarming' number of people living with undiagnosed diabetes — particularly youth.
  • Will Wegovy Be of Little Use for Weight Loss? The weight loss drug heralded as a 'game changer' may be of little use unless we take care of a few hurdles first, says Dr Akshay Jain.
  • Top Studies, Highlights From ADA 2021   Drs Akshay Jain and Harpreet Bajaj give us their takes on the clinically relevant highlights from ADA 2021.
  • Disparities in SGLT2i Use: Patient Barriers or Physician Bias? A recent study suggests that although the use of SGLT2 inhibitors has increased overall, certain groups are not being prescribed these medications. Dr Akshay Jain looks into possible reasons why.
  • EASD 2020 GLP-1 Receptor Agonists at EASD 2020: Poster Pearls Dr Akshay Jain shares his top poster picks on GLP-1 receptor agonists from this year's EASD virtual meeting.
  • EASD 2020 New Diabetes Guidelines: 'Treat to Mitigate' Dr Akshay Jain reviews the new position statement from Primary Care Diabetes Europe on the management of type 2 diabetes.
  • EASD 2020 Once-Weekly 'Centennial Insulin': Will It Live Up to the Promise? One hundred years after the discovery of insulin, we are approaching a new frontier in diabetes management, says Dr Harpreet Bajaj.
  • Obesity and the Bitter Pill of Truth Obesity is encountered ubiquitously in clinical practice, with rates continuing to rise -- but why? Perhaps it's time we face the truth, says Dr Akshay Jain.
  • CGM in Type 2 Diabetes: Invaluable or Too Expensive? Is the value of using CGM in people with type 2 diabetes worth the cost? Dr Akshay Jain comments on a debate from ADA 2020.
  • VERTIS-CV Results 'Disappoint,' Raise More Questions The VERTIS-CV trial results presented at the ADA meeting raise more questions about the benefits of SGLT2 inhibitors than they answer, says Dr Harpreet Bajaj.
  • Is COVID-19 Fueling the Fire of Opinion-Based Medicine? This pandemic is causing people to turn to the 'pseudosciences' in their desperation to quickly save the world, writes Harpreet Bajaj.
  • The Links Between COVID-19 and Diabetes, Known and Unknown Dr Harpreet Bajaj summarizes the known and unknown links between diabetes and COVID-19, focusing on three clinical questions.
  • Cardios, Nephros, PCPs -- We're All Diabetologists Now Newer diabetes medications are proving effective in reducing CV events, hospitalizations for heart failure, and progression to dialysis. So where do these drugs belong?
  • Top 5 Diabetes Highlights From 2019 For the first time in several years, a cardiovascular outcomes trial may not be the most exciting diabetes news of the year. Here are 2019's highlights from Dr Harpreet Bajaj.